{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:19:15Z","timestamp":1791051555612,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.pharmthera.2013.09.003","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T01:00:15Z","timestamp":1380243615000},"page":"117-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Bevacizumab and micrometastases: Revisiting the preclinical and clinical rollercoaster"],"prefix":"10.1016","volume":"141","author":[{"given":"Giannis","family":"Mountzios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Carmeliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2013.09.003_bb0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2012.44.4711","article-title":"Bevacizumab in stage II\u2013III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial","volume":"31","author":"Allegra","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0010","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1158\/1078-0432.CCR-09-3100","article-title":"Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy","volume":"16","author":"Bagri","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0015","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.molmed.2010.01.004","article-title":"Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale","volume":"16","author":"Bagri","year":"2010","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1535-6108(03)00194-6","article-title":"The hypoxic response of tumors is dependent on their microenvironment","volume":"4","author":"Blouw","year":"2003","journal-title":"Cancer cell"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0025","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1200\/JCO.2012.41.9242","article-title":"Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies","volume":"30","author":"Bottsford-Miller","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0030","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0035","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/annonc\/mdn540","article-title":"Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery","volume":"19","author":"Cacheux","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0040","series-title":"San Antonio breast cancer conference, Abstract number S6-5","article-title":"Adjuvant bevacizumab did not improve invasive disease-free survival in triple-negative breast cancer","author":"Cameron","year":"2012"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0050","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nature reviews","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Drug Discov"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0055","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/path.4052","article-title":"Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors","volume":"227","author":"Chung","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0060","first-page":"393","article-title":"Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nature reviews","volume":"8","author":"De Bock","year":"2011","journal-title":"Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0065","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","article-title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial","volume":"13","author":"de Gramont","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0070","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1158\/1078-0432.CCR-08-0260","article-title":"Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas","volume":"14","author":"Desjardins","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0075","first-page":"210","article-title":"Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nature reviews","volume":"8","author":"Ebos","year":"2011","journal-title":"Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0205","doi-asserted-by":"crossref","first-page":"17069","DOI":"10.1073\/pnas.0708148104","article-title":"Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy","volume":"104","author":"Ebos","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0210","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer cell"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0215","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0220","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews","volume":"3","author":"Ferrara","year":"2004","journal-title":"Drug Discov"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0225","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0230","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.pharmthera.2013.09.003_bb0235","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1074\/jbc.M507783200","article-title":"Structure\u2013function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab","volume":"281","author":"Fuh","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0240","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1126\/science.1150224","article-title":"Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis","volume":"319","author":"Gao","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0245","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.14570","article-title":"Population pharmacokinetics of bevacizumab","volume":"26","author":"Gaudreault","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0250","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ctrv.2011.12.008","article-title":"A preclinical and clinical review of aflibercept for the management of cancer","volume":"38","author":"Gaya","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0255","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1517\/14712590903208883","article-title":"VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy","volume":"9","author":"Greenberg","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0260","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0265","first-page":"297","article-title":"Antiangiogenic therapy\u2014evolving view based on clinical trial results. Nature reviews","volume":"9","author":"Jayson","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0270","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.1125950","article-title":"Antiangiogenic therapy: a universal chemosensitization strategy for cancer?","volume":"312","author":"Kerbel","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0275","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nm.2072","article-title":"Real-time imaging reveals the single steps of brain metastasis formation","volume":"16","author":"Kienast","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0280","doi-asserted-by":"crossref","first-page":"11399","DOI":"10.1073\/pnas.172398399","article-title":"Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma","volume":"99","author":"Kim","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0285","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1158\/1535-7163.MCT-08-0596","article-title":"In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models","volume":"8","author":"Kolinsky","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0290","first-page":"6624","article-title":"Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2","volume":"61","author":"Kunkel","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0295","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1470-2045(12)70231-0","article-title":"VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials","volume":"13","author":"Lambrechts","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0300","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/BC20110069","article-title":"Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer","volume":"103","author":"Le Guelte","year":"2011","journal-title":"Biol Cell"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0305","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.bjc.6605514","article-title":"Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity","volume":"102","author":"Lee","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0310","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0315","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","article-title":"Clinical pharmacokinetics of bevacizumab in patients with solid tumors","volume":"62","author":"Lu","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0320","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2012.05.037","article-title":"VEGF inhibits tumor cell invasion and mesenchymal transition through a MET\/VEGFR2 complex","volume":"22","author":"Lu","year":"2012","journal-title":"Cancer cell"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0325","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.1158\/1078-0432.CCR-08-0243","article-title":"Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model","volume":"14","author":"Mabuchi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0080","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cell.2009.01.020","article-title":"Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization","volume":"136","author":"Mazzone","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2010.30.2794","article-title":"Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials","volume":"29","author":"Miles","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0090","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0100","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1158\/1535-7163.MCT-08-0182","article-title":"Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib","volume":"7","author":"Padera","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0105","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"Paez-Ribes","year":"2009","journal-title":"Cancer cell"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0110","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/1535-7163.MCT-11-0742-T","article-title":"Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model","volume":"11","author":"Pastuskovas","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semcancer.2011.01.002","article-title":"The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts","volume":"21","author":"Peinado","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0120","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0125","first-page":"963","volume":"57","author":"Relf","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0130","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0135","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","article-title":"Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors","volume":"2","author":"Sennino","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0140","first-page":"699","article-title":"Controlling escape from angiogenesis inhibitors. Nature reviews","volume":"12","author":"Sennino","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2013.09.003_bb0145","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/path.4053","article-title":"Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models","volume":"227","author":"Singh","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0155","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/0008-5472.CAN-11-2464","article-title":"Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion","volume":"72","author":"Sorensen","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0160","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1634\/theoncologist.2008-0016","article-title":"Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage","volume":"13","author":"Stein","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0165","first-page":"14","article-title":"Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nature reviews","volume":"10","author":"Tanaka","year":"2013","journal-title":"Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0170","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10585-012-9543-8","article-title":"Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy","volume":"30","author":"Tanaka","year":"2013","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0175","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ejca.2007.08.017","article-title":"The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales","volume":"43","author":"Tappenden","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11120","article-title":"Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer","volume":"11","author":"Tappenden","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0185","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1200\/JCO.2011.39.9824","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0190","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","article-title":"Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs","volume":"21","author":"Van der Veldt","year":"2012","journal-title":"Cancer cell"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0195","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of myeloid immune suppressor Gr+CD11b+cells in tumor-bearing host directly promotes tumor angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer cell"},{"key":"10.1016\/j.pharmthera.2013.09.003_bb0200","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1158\/0008-5472.CAN-10-2527","article-title":"VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer","volume":"71","author":"You","year":"2011","journal-title":"Cancer Res"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813001927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813001927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T22:22:23Z","timestamp":1564093343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725813001927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0163725813001927"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.09.003","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bevacizumab and micrometastases: Revisiting the preclinical and clinical rollercoaster","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}